1-3 of 3
Luke A. Masterson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody–Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine Dimer

Stephen J. Gregson, Kathryn Pugh, Neki Patel, Shameen Afif-Rider, Balakumar Vijayakrishnan, Kathleen Santos, Jitka Riedl, Ian Hutchinson, Gyoung-Dong Kang, K. Phin Chooi, Rhiannon Beard, Lauren Adams, Conor S. Barry, Kathryn Ball, Luke A. Masterson, Mary McFarlane, John A. Hartley, Philip W. Howard
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (9): 1439–1448.
https://doi.org/10.1158/1535-7163.MCT-22-0145
Published: 06 September 2022
View articletitled, Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody–Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine Dimer
Open the PDF for Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody–Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine Dimer in another window
Includes: Supplementary data
Journal Articles

Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATR

Shenlan Mao, Raghothama Chaerkady, Wen Yu, Gina D’Angelo, Andrew Garcia, Hong Chen, Allison M. Barrett, Sandrina Phipps, Ryan Fleming, Sonja Hess, Jens-Oliver Koopmann, Nazzareno Dimasi, Susan Wilson, Kathryn Pugh, Kimberly Cook, Luke A. Masterson, Changshou Gao, Herren Wu, Ronald Herbst, Philip W. Howard, David A. Tice, Mark Cobbold, Jay Harper
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2021) 20 (3): 541–552.
https://doi.org/10.1158/1535-7163.MCT-20-0351
Published: 02 March 2021
View articletitled, Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATR
Open the PDF for Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATR in another window
Includes: Supplementary data
Journal Articles

ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies

Michael J. Flynn, Francesca Zammarchi, Peter C. Tyrer, Ayse U. Akarca, Narinder Janghra, Charles E. Britten, Carin E.G. Havenith, Jean-Noel Levy, Arnaud Tiberghien, Luke A. Masterson, Conor Barry, Francois D'Hooge, Teresa Marafioti, Paul W.H.I. Parren, David G. Williams, Philip W. Howard, Patrick H. van Berkel, John A. Hartley
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (11): 2709–2721.
https://doi.org/10.1158/1535-7163.MCT-16-0233
Published: 01 November 2016
View articletitled, ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
Open the PDF for ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies in another window
Includes: Supplementary data